BridgeBio Raises Price Targets After Q4 Revenue Beat and 35% Attruby Growth
BridgeBio pre-announced Q4 Attruby sales of $146M, up 35% sequentially, and reported Q4 revenue of $154.18M versus a $149.07M consensus. Truist and Morgan Stanley raised price targets to $95 and $98 respectively, while reaffirming Buy and Overweight ratings on strong Phase 3 readouts.
1. Q4 Financial Performance
BridgeBio reported Q4 revenue of $154.18 million, surpassing the $149.07 million consensus, and posted EPS of -$1.00 versus estimates of -$0.67. The company pre-announced Attruby sales of $146 million, a 35% sequential increase driven by accelerating new patient additions.
2. Analyst Revisions
Truist raised its price target to $95 from $86 and maintained a Buy rating, citing robust Q4 sales momentum. Morgan Stanley lifted its target to $98 from $96 and reiterated an Overweight rating after updating estimates following the quarterly report.
3. Pipeline and Outlook
Co-Founder and CEO Neil Kumar highlighted three successful Phase 3 readouts delivered within just over three months, underscoring the company’s scientific rigor. He expressed optimism that this progress could result in six approved products as BridgeBio approaches its ten-year milestone.